Abstract: The present invention relates to vaccine compositions for treatment of substance use disorders, methods for the manufacture thereof, and methods for the use thereof to treat an animal. These compositions comprise a hapten conjugated via a linker to a protein scaffold and mixed with a particulate carrier and at least one immunostimulatory adjuvant molecule.
Abstract: The present invention relates to vaccine compositions for treatment of substance use disorders, methods for the manufacture thereof, and methods for the use thereof to treat an animal. These compositions comprise a hapten conjugated via a linker to a protein scaffold and mixed with a particulate carrier and at least one immunostimulatory adjuvant molecule.
Abstract: The present invention relates to vaccine compositions for treatment of substance use disorders, methods for the manufacture thereof, and methods for the use thereof to treat an animal. These compositions comprise a hapten conjugated via a linker to a protein scaffold and mixed with a particulate carrier and at least one immunostimulatory adjuvant molecule.
Abstract: The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).
Type:
Grant
Filed:
April 2, 2018
Date of Patent:
August 6, 2019
Assignees:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, MOLECULAR EXPRESS, INC.
Inventors:
Gary Fujii, Francis C. Szoka, Douglas S. Watson
Abstract: The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).
Type:
Application
Filed:
April 2, 2018
Publication date:
October 4, 2018
Applicants:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, MOLECULAR EXPRESS, INC.
Inventors:
Gary FUJII, Francis C. SZOKA, Douglas S. WATSON
Abstract: The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).
Type:
Grant
Filed:
June 13, 2016
Date of Patent:
April 3, 2018
Assignees:
MOLECULAR EXPRESS, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Gary Fujii, Francis C. Szoka, Jr., Douglas S. Watson
Abstract: The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).
Type:
Grant
Filed:
June 30, 2014
Date of Patent:
June 14, 2016
Assignees:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, MOLECULAR EXPRESS, INC.
Inventors:
Gary Fujii, Francis C. Szoka, Jr., Douglas S. Watson
Abstract: The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise liposomes formed from dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol; and an antigenic polypeptide comprising a first polypeptide sequence, and a second polypeptide sequence heterologous the first polypeptide sequence which comprises a transmembrane sequence from a membrane protein, said transmembrane sequence having a number of residues sufficient to cross a lipid bilayer, at least nine contiguous residues of which are predicted to form an alpha helix having a hydrophobicity score of about 0.7 or greater.
Type:
Application
Filed:
April 25, 2012
Publication date:
September 25, 2014
Applicant:
MOLECULAR EXPRESS, INC.
Inventors:
Gary Fujii, William A. Ernst, Jill Adler-Moore, Linda Vician
Abstract: The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).
Type:
Grant
Filed:
March 9, 2010
Date of Patent:
July 1, 2014
Assignees:
The Regents of the University of California, Molecular Express, Inc.
Inventors:
Gary Fujii, Francis C. Szoka, Jr., Douglas S. Watson